Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy Therapeutics
Pharmaceutical company raises GBP 16M, seeks admission to AIM
November 6th, 2004
Allergy Therapeutics, a pharmaceuticals company focused on allergy vaccines, announced that it has successfully placed 21,917,808 new ordinary shares at 73 pence per share, conditional on its admission to trading on the Alternative Investment Market (AIM). The placing was fully subscribed, raising the target of GBP15 million net of expenses. It is expected that the company's shares were to begin trading on AIM on October 11. KBC Peel Hunt is acting as the nominated adviser and broker to Allergy Therapeutics. Commenting on the fundraising and admission to AIM, Keith Carter, chief executive of Allergy Therapeutics, said: ...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
